VRCA - ヴェリカ・ファ―マシュ―ティカルズ (Verrica Pharmaceuticals Inc.) ヴェリカ・ファ―マシュ―ティカルズ

 VRCAのチャート


 VRCAの企業情報

symbol VRCA
会社名 Verrica Pharmaceuticals Inc (ヴェリカ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Verrica Pharmaceuticals Inc. is a United States-based clinical-stage medical dermatology company. The Company is focused on identifying developing and commercializing pharmaceutical products for the treatment of skin diseases with unmet needs. Its lead product candidate VP-102 is a drug-device combination of topical solution of cantharidin. The Company also intends to develop second cantharidin-based product candidate VP-103 for the treatment of plantar warts. The Company has completed one Phase II clinical trial of topical solution of cantharidin administered with the wooden stick part of a cotton-tipped swab. It also conducting another Phase II clinical trial of topical solution of cantharidin administered through applicator which collectively refer to as VP-102 for the treatment of molluscum.   ヴェリカ・ファ―マシュ―ティカルズは米国の医薬品企業。皮膚疾患の治療法の特定、治療薬の開発および商品化に焦点を当て臨床試験を行う。主に小児ウイルス性皮膚疾患である軟体動物感染症や、一般的ないぼの治療薬の開発を手掛ける。主力製品には、独自の局所療法であるVP-102がある。本社所在地はペンシルバニア州ウエストチェスタ―。   Verrica Pharmaceuticals Inc a clinical-stage medical dermatology company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs.
本社所在地 10 North High Street Suite 200 West Chester PA 19380 USA
代表者氏名
代表者役職名
電話番号 +1 434-980-8100
設立年月日 41456
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数
url www.verrica.com
nasdaq_url https://www.nasdaq.com/symbol/vrca
adr_tso
EBITDA EBITDA(百万ドル) -10.81400
終値(lastsale) 14.15
時価総額(marketcap) 363603649.65
時価総額 時価総額(百万ドル) 354.35300
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 251.20400
当期純利益 当期純利益(百万ドル) -10.62700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Verrica Pharmaceuticals Inc revenues was not reported. Net loss increased from $1.7M to $7.8M. Higher net loss reflects Research and development - Balancing val increase from $1.5M to $4.1M (expense) General and administrative - Balancing v increase from $118K to $2.4M (expense) Stock-Based Compensation in SG&A increase from $0K to $1.1M (expense).

 VRCAのテクニカル分析


 VRCAのニュース

   Microcaps mostly among midday movers  2018-12-26
Gainers: Adial Pharmaceuticals (NASDAQ: ADIL ) +31% . Plug Power (NASDAQ: PLUG ) +25% . Remark Holdings (NASDAQ: MARK ) +24% . Verrica Pharmaceuticals (NASDAQ: VRCA ) +22% . Altisource Asset Management (NYSEMKT: AAMC ) +21% . XTL Biopharmaceuticals (NASDAQ: XTLB ) +20% . NF Ene…

 関連キーワード  (医薬品 米国株 ヴェリカ・ファ―マシュ―ティカルズ VRCA Verrica Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)